Journal of global antimicrobial resistance最新文献

{"title":"Clinical reality for adjunctive rifampin usage in infective endocarditis treatment","authors":"Elif Mukime Sarıcaoğlu ,&nbsp;Nuran Sarı ,&nbsp;Merve Aslan ,&nbsp;Yasemin Tezer Tekce ,&nbsp;Yesim Uygun Kizmaz ,&nbsp;Serap Simsek Yavuz ,&nbsp;Ozlem Azap ,&nbsp;Türkiye Endocarditis Group","doi":"10.1016/j.jgar.2024.10.015","DOIUrl":"10.1016/j.jgar.2024.10.015","url":null,"abstract":"<div><h3>AIM</h3><div>We aimed to determination of the area of adjunctıve rifampin usage in infectıve endocarditis (IE) endocarditis treatment.</div></div><div><h3>BACKGROUND</h3><div>Current International infective endocarditis guidelines recommend rifampin-based combination treatments for staphylococcal prosthetic valve endocarditis (PVE). It is also a frequently used agent in the treatment of culture-negative endocarditis and brucella endocarditis. Because the rifampin tolerability is an important issue, full compliance with the guidelines in treatment management may not always be achieved.</div></div><div><h3>METHODS</h3><div>This study was a multicenter, retrospective cohort study, performed between 2019-2023. The patients used rifampin based combinations (RBC) were included in the study. Demographic, imaging, microbiological and clinical data were recorded. Descriptive statistical analysis was performed.</div></div><div><h3>RESULTS</h3><div>Between January 2019 and December 2023; a total of 506 IE cases were detected. A total of 59 patients used RBC during treatment. The median duration of rifampin treatment in these patients was 34.5(2-200) days. 28 of these patients were staphylococcal endocarditis (20 prosthetic valve IE, 5 cardiac implanted electronic device IE, 3 native valve IE). Fourteen (23.7%) of these patients were followed-up as culture negative IE. The patients diagnosed with The median duration of RBC in brucella endocarditis patients (6) was 139(20-180) days. RBC was not used in 58.7% of patients with prosthetic staphylococcal infective endocarditis. Although not compliant with guideline recommendations, RBC was used in 11 patients with a median duration of 20 days.</div></div><div><h3>CONCLUSION</h3><div>In order to determine the areas of use of rifampin, which is difficult to tolerate and has many drug interactions, in the treatment of endocarditis, needs further validation.</div></div>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":"39 ","pages":"Pages 5-6"},"PeriodicalIF":3.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143344044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detection of resistance genes and evaluation of synergistic effects of antibiotic combinations in colistin-resistant Klebsiella pneumoniae clinical isolates","authors":"Hatice Dilara Karakuş ,&nbsp;Bulent Durdu ,&nbsp;SERCAN KESKIN ,&nbsp;Mehmet Ziya Doymaz ,&nbsp;Turan Aslan","doi":"10.1016/j.jgar.2024.10.053","DOIUrl":"10.1016/j.jgar.2024.10.053","url":null,"abstract":"<div><h3>OBJECTIVE</h3><div>Rising antimicrobial resistance in <em>Klebsiella pneumoniae</em> is major public health issue, linked to high morbidity, and mortality. This study aims to identify resistance genes in <em>Klebsiella pneumoniae</em> strains from a university hospital in Istanbul, and to determine effects of combining several commonly used antibiotics.</div></div><div><h3>BACKGROUND</h3><div>Excessive antibiotic use has increased prevalence of antibiotic resistance in <em>Klebsiella pneumoniae</em> isolates severely limiting treatment options for clinicians.</div></div><div><h3>METHODS</h3><div>Twenty-one consecutive resistant <em>Klebsiella pneumoniae</em> isolates from various samples from Hospitals of Bezmialem Vakıf University were analyzed. Identifications and susceptibilities were done using commercial methods (VITEK MS, VITEK®2, bioMérieux). Colistin resistance was assessed by microdilution test and resistance genes (blaKPC, blaOXA48, blaNDM) were detected via PCR using specific primers. Checkerboard testing was used to determine colistin(C), meropenem(M), gentamycin(G), trimethoprim/sulphamethoxazole(B), ceftazidime/avibactam(S), and tigecycline(T) susceptibilities singly or in combinations.</div></div><div><h3>RESULTS</h3><div>All strains were blaOXA48 positive whereas 19% blaNDM positive, and 4.7% blaKPC positive. Preliminary data showed synergism in significant number of isolates particularly in C+S, C+M, and C+T combinations, though not uniformly. Also, significant amount of additive effect and indifferent interactions, where antibiotics did not interact with each other, were noticed in different isolate-antibiotic combinations. It should be underlined that these data are preliminary, and clearer picture may be obtained by increasing number of samples.</div></div><div><h3>CONCLUSIONS</h3><div>While detection of blaOXA-48 in all strains is expected, detection of blaKPC in 4.7% and blaNDM in 19% of strains is concerning. Significant interactions were noted with some antibiotic combinations and further testing with large number of isolates is suggested.</div></div>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":"39 ","pages":"Page 17"},"PeriodicalIF":3.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143344060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In-Vitro Antimicrobial Susceptibility Results of Brucella Species in Eastern Türkiye","authors":"Merve Kılıç Tekin ,&nbsp;Enes Erbağcı ,&nbsp;Neşe İnal","doi":"10.1016/j.jgar.2024.10.100","DOIUrl":"10.1016/j.jgar.2024.10.100","url":null,"abstract":"<div><h3>BACKGROUND</h3><div>Brucellosis stands as the prevalent zoonotic infection globally. This disease places substantial economic burdens and presents challenges to public health. Regular monitoring of antimicrobial susceptibilities is crucial due to documented instances of treatment failures, relapses, and resistance observed in studies.</div></div><div><h3>AIM</h3><div>The study aimed to assess the sensitivity of antimicrobial agents against <em>Brucella</em> spp.</div></div><div><h3>METHODS</h3><div>Between January 2023 and June 2024, 45 <em>Brucella</em> isolates were included. Species identification was achieved 16S rRNA analysis. The strains were inoculated on Mueller-Hinton agar supplemented with 5% horse blood and β-NAD, followed by incubation with eight antibiotic discs. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) 2024 guideline was used.</div></div><div><h3>RESULTS</h3><div>Among 45 participants, 46.7% were women and 53.3% were men, with an average age of 41.3 years (±15.6). Species determination through 16S rRNA analysis revealed <em>Brucella melitensis</em> in 36 (80%) patients and <em>Brucella abortus</em> in 9 (20%) patients. Gentamicin, rifampicin, ceftriaxone, tetracycline, trimethoprim-sulfamethoxazole and streptomycin were detected sensitive. Levofloxacin and ciprofloxacin were determined susceptible increased exposure 84.5% and 95.6% rate respectively. No difference was detected between <em>Brucella melitensis</em> and <em>Brucella abortus</em> regarding their susceptibility to antimicrobial agents (Table 1).</div></div><div><h3>CONCLUSION</h3><div>Our study predominantly identified increased exposure patterns for ciprofloxacin and levofloxacin, suggesting that quinolone resistance could pose future challenges in treating brucellosis. Monitoring antibiotic resistance in <em>Brucella</em> isolates is crucial for disease management. Regular surveillance of resistance distribution and prevalence among isolates in endemic countries is essential. This data could inform updates to treatment guidelines and aid in disease control efforts.</div></div>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":"39 ","pages":"Page 32"},"PeriodicalIF":3.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143344279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of hospital antibiotic prescription patterns using WHO AWaRe Classification in Karachi, Pakistan","authors":"Nosheen Nasir,&nbsp;Beenish Khalid Mehmood,&nbsp;Safia Awan,&nbsp;Saadia Sattar,&nbsp;Salma Tajuddin","doi":"10.1016/j.jgar.2024.10.091","DOIUrl":"10.1016/j.jgar.2024.10.091","url":null,"abstract":"<div><h3>Background</h3><div>Antimicrobial resistance poses a significant and escalating public health threat. One of the biggest drivers of AMR is the misuse and overuse of antibiotics. Pakistan is the third-highest antibiotic-consuming country among low- and middle-income countries (LMICs). Our study aims to evaluate antibiotic consumption using the WHO AWaRe Classification in hospitalized patients from 2016 to 2023 at a major tertiary care academic medical center in Karachi, Pakistan.</div></div><div><h3>METHODS</h3><div>This retrospective study examined inpatient antibiotic utilization by extracting data from Electronic Medical Records and pharmacy services at Aga Khan University Hospital in Karachi between 2016 and 2023. Data was collected on patient demographics, antibiotic types, and prescription counts. The consumption of each antibiotic was converted to defined daily dose (DDD)/1,000 patient-days.</div></div><div><h3>RESULTS</h3><div>During the period from January 2016 to September 2023, a total of 267,972 antibiotics were prescribed. WATCH antibiotics were the most prescribed, ranging from 68.8% to 73.9% of prescriptions followed by ACCESS antibiotics (58-63.9%) of prescriptions between 2016 and 2023 in hospitalized patients. There was a trend towards an increase in prescriptions of RESERVE antibiotics from 3.8% to 5.3% (p&lt;0.001) and a decrease in prescriptions of ACCESS antibiotics from 63.9% to 58 %(p&lt;0.001) (Figure 1).</div></div><div><h3>CONCLUSION</h3><div>Our study identified a notable increase in the utilization of WATCH group antibiotics compared to ACCESS group and an alarming increase in the utilization of RESERVE group antibiotics. These findings underscore the shifting patterns in antibiotic usage, emphasizing the importance of monitoring and strategic interventions to promote responsible antibiotic prescribing practices.</div></div>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":"39 ","pages":"Page 29"},"PeriodicalIF":3.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143344668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reviewer Acknowledgement 2024","authors":"","doi":"10.1016/j.jgar.2024.12.001","DOIUrl":"10.1016/j.jgar.2024.12.001","url":null,"abstract":"","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":"39 ","pages":"Pages 266-267"},"PeriodicalIF":3.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143161438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Monte Carlo simulation for dosage optimization of the best available therapy for bloodstream infections secondary to carbapenemase-producing Klebsiella pneumoniae in critically ill patients","authors":"Sujareenoot Suya ,&nbsp;Worapong Nasomsong ,&nbsp;Wichai Santimaleeworagun ,&nbsp;Piraporn Juntanawiwat ,&nbsp;Tassananwan Chatreewonanakul ,&nbsp;Weerayuth Saelim","doi":"10.1016/j.jgar.2024.10.263","DOIUrl":"10.1016/j.jgar.2024.10.263","url":null,"abstract":"<div><h3>Objective</h3><div>We aimed to use Monte Carlo simulation, based on pharmacokinetic/pharmacodynamic targets, to investigate and determine the optimal dosage of the available combination therapies for carbapenem-resistant <em>Klebsiella pneumoniae</em> (CRKP) in critically ill patients.</div></div><div><h3>Methods</h3><div>We collected CRKP clinical isolates from Phramongkutklao Hospital between October 2020 and June 2022. A molecular study of resistant genes was performed using polymerase chain reaction. Broth microdilution checkerboards were used to evaluate the mono- and synergistic antibiotic activities. Monte Carlo simulation was used to determine the optimal antibiotic regimens, based on the probability of target attainment (PTA) and cumulative fraction of response.</div></div><div><h3>Results</h3><div>The 54 CRKP isolates were resistant to tigecycline (100%), colistin (75.9%), amikacin (70.4%), and gentamicin (63.0%). The most common carbapenemase genotype was <em>bla_{oxacillinases (OXA)-48-like}</em> (42.6%), followed by <em>bla_{New Delhi metallo beta-lactamase (NDM)}</em> (29.6%) and coexistence of <em>bla_OXA-48-like</em> and <em>bla_NDM</em> (22.2%). Based on the PTA, synergistic and additive activities against CRKP isolates were observed with appropriate dosages of tigecycline–colistin (67.9%), tigecycline–gentamicin (62.2%), and tigecycline–amikacin (51.4%).</div></div><div><h3>Conclusions</h3><div>Tigecycline–colistin was the best available combination therapy for critically ill patients with CRKP, especially NDM. When used in combination with tigecycline, a colistin creatinine clearance of &lt;90 mL/min can raise the cumulative fraction of response target and less nephrotoxicity.</div></div>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":"39 ","pages":"Pages 257-265"},"PeriodicalIF":3.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142639128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Susceptibility of Enterobacterales Collected in the Middle East and Turkey to Aztreonam/Avibactam and Comparator Agents Stratified by Infection Source: ATLAS Surveillance Program 2018-2022","authors":"Mark Wise ,&nbsp;Gregory Stone ,&nbsp;Katherine Perez ,&nbsp;Daniel Sahm ,&nbsp;Meredith Hackel","doi":"10.1016/j.jgar.2024.10.038","DOIUrl":"10.1016/j.jgar.2024.10.038","url":null,"abstract":"<div><h3>BACKGROUND</h3><div>Aztreonam-avibactam (ATM-AVI) is a combination of aztreonam, notable for its stability to metallo-β-lactamases (MBLs), and avibactam, an inhibitor of class A, class C and some class D β-lactamases that inactivate aztreonam and are frequently co-carried with MBLs. ATM-AVI was recently approved in EU for treatment of adult patients with complicated intra-abdominal infections, hospital- and ventilator-associated pneumonia, and complicated urinary tract infections. This study evaluated the activity of ATM-AVI and comparators against Enterobacterales collected in six Middle Eastern countries from various infection sources, including lower respiratory tract infections (LRTI), urinary tract infections (UTI), intra-abdominal infections (IAI), skin and soft tissue infections (SSTI) and bloodstream infections (BSI).</div></div><div><h3>METHODS</h3><div>From 2018-2022, 6,326 non-duplicate Enterobacterales were collected from 17 hospitals in Israel, Jordan, Kuwait, Qatar, Saudi Arabia and Turkey for which infection source was specified. Susceptibility testing was performed by broth microdilution and interpreted using 2024 EUCAST breakpoints.</div></div><div><h3>RESULTS</h3><div>ATM-AVI showed excellent in vitro activity against isolates from all infection sources as evidenced by low MIC90 values (0.25 mg/L for BSI, IAI and LRTI isolates; 0.12 mg/L for SSTI and UTI isolates). Overall, ≥99.4% of the population from each infection type was susceptible to ATM-AVI. Among comparators, meropenem (88.0% - 94.4% susceptible) and amikacin (88.1% - 94.5%) were also active. The addition of AVI to ATM increased the susceptibility rate by &gt;35 percentage points for each infection source over ATM alone.</div></div><div><h3>CONCLUSIONS</h3><div>ATM-AVI was the most potent agent examined regardless of infection source and offers promise for use against multidrug-resistant Enterobacterales, including MBL-carriers.</div></div>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":"39 ","pages":"Pages 12-13"},"PeriodicalIF":3.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143343764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prolonged Infusions of Meropenem in Pediatric Infections with Carbapenem Resistant Gram Negative Bacteria","authors":"Sevgen Tanır Basaranoglu ,&nbsp;Ayşe Istanbullu","doi":"10.1016/j.jgar.2024.10.045","DOIUrl":"10.1016/j.jgar.2024.10.045","url":null,"abstract":"<div><div>In many pediatric wards, infections caused by GNB are increasingly resulting in significant morbidity and mortality. For the infections with CR-GNB, a choice of treatment in children is prolonged infusions of carbapenem, particularly the meropenem. To assess the effectiveness of prolonged meropenem infusion (PMI) in children with carbapenem resistant (CR) Gram negative bacteria (GNB) infections.</div><div>The present study included pediatric patients between 1 month and 18 years of age who were hospitalised and presented with bacteremia with a positive blood culture with CR-GNB. We analysed the causative microorganism, susceptibility profile, the antimicrobials used in combination with PMI. Outcome measures were negative blood culture 14-day and 30-day mortality, and recurrence of infection in 14 days of completion of treatment.</div><div>Between Jun 2022 and July 2024, a total of 19 (10 male, 9 female) children with 26 infections were recorded. The most common underlying disease was hemato-oncological disease, followed by chronic lung disease. Among the causative microorganisms, n=16 (61%) {Klebsiella} spp, n=7 (27%) {Pseudomonas} spp., n=1 (3.8%) {Ochromobacter} spp, n=1 (3.8%) {E. coli } were detected. Three infections recurred in the 14 days of completion of treatment. Seven (36.8%) patients died within 14 days of infection. Four of the patients who died had bone marrow transplant, one had chronic pulmonary disease, one with renal transplantation, and one had operated congenital heart effect.</div><div>In pediatric infections with CR-GNB, PMI in combination with other GNB-active agents may be a reasonable choice. The mortality is closely related to the underlying disease and immune status.</div></div>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":"39 ","pages":"Pages 14-15"},"PeriodicalIF":3.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143343765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antibiotic resistance genes in rural public places mirror the pattern of clinical antibiotic resistance prevalence","authors":"Dhammika Leshan Wannigama ,&nbsp;Shuichi Abe ,&nbsp;Cameron Hurst ,&nbsp;Yu Suzuki ,&nbsp;Kazunori Moriya ,&nbsp;Yoshikazu Okuma ,&nbsp;Ayaka Tateno ,&nbsp;Paul G. Higgins ,&nbsp;Mohan Amarasiri","doi":"10.1016/j.jgar.2024.10.027","DOIUrl":"10.1016/j.jgar.2024.10.027","url":null,"abstract":"<div><h3>AIM AND BACKGROUND</h3><div>The World Health Organization's global action plan on antimicrobial resistance emphasizes the importance of integrated antibiotic resistance (AR) surveillance. Public spaces are crucial for both recipients and contributors to AR.</div></div><div><h3>METHODS</h3><div>This study, conducted in Yamagata Prefecture, Japan, addresses the rising prevalence of clinical AR by examining the prevalence of AR genes in public places (n=900). We analyzed 229 resistance genes and 25 mobile genetic elements using advanced quantitative polymerase chain reaction methods.</div></div><div><h3>RESULTS</h3><div>This first large rural surveillance in Japan showed that AR profiles mirror the AR gradient observed in clinics. Locational variations were identified in AR gene patterns. The most abundant were AMR genes encoding resistance toward multi drug resistance, tetracyclines, aminoglycosides, beta-lactams, and sulfonamides. A total of 27 ARGs were detected in at least half of the locations. The genetic landscapes of ampC, blaNDM-1, blaKPC, blaVIM, blaIMP, bla-CTXM, mecA, or blaIMP and vanA genes displayed significant diversity.</div></div><div><h3>CONCLUSION</h3><div>These findings underscore the necessity for regular surveillance and control measures tailored to the distinct geographic regions, to address antibiotic resistance effectively.</div></div>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":"39 ","pages":"Page 9"},"PeriodicalIF":3.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143343932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal trends of enterococcal and vancomycin-resistant Enterococcus faecium bacteraemias in the northern Dutch-German cross-border region: a ten-year multicentre analysis","authors":"Cansu Çimen ,&nbsp;Andreas Voss ,&nbsp;Joseph Hellkamp ,&nbsp;Axel Hamprecht ,&nbsp;Matthijs Berends","doi":"10.1016/j.jgar.2024.10.049","DOIUrl":"10.1016/j.jgar.2024.10.049","url":null,"abstract":"<div><h3>INTRODUCTION</h3><div>Enterococcus species, particularly E. faecium and E. faecalis, are prominent causes of bacteraemia, posing significant clinical challenges due to antibiotic resistance. The incidence of enterococcal bacteraemia, especially vancomycin-resistant E. faecium (VREfm), has been rising in Europe. This study aims to map the trends in enterococcal bacteraemia and VREfm in the Northern Dutch-German cross-border region over a decade.</div></div><div><h3>METHODS</h3><div>We conducted a retrospective cross-sectional study at the Dutch University Medical Center Groningen (UMCG) and German Klinikum Oldenburg (KOL) from January 1, 2013, to December 31, 2022. Data on enterococcal bacteraemia episodes, patient demographics, and antibiotic resistance were collected from blood cultures.</div></div><div><h3>RESULTS</h3><div>A total of 1,822 episodes of enterococcal bacteraemia were identified, of which 733 at KOL and 1,089 at UMCG. VRE bacteraemia was significantly higher at KOL (67 cases) compared to UMCG (7 cases). Median ages for enterococcal bacteraemia were 67 years at KOL and 61 years at UMCG. The majority of cases were in males (68.2% at KOL, 63.4% at UMCG). Haematology/Oncology wards accounted for approximately 48% of enterococcal bacteraemia cases in both hospitals.</div></div><div><h3>DISCUSSION</h3><div>Our findings reveal significant institutional and regional differences in the incidence and characteristics of enterococcal bacteraemia. These discrepancies highlight the need for localized surveillance for understanding the epidemiology of enterococcal bacteraemia, and tailored infection control strategies. The high burden of bacteraemia in Haematology/Oncology wards underscores the vulnerability of immunocompromised patients. Enhanced cross-border collaboration and data sharing are crucial for effective infection control in this interconnected region.</div></div>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":"39 ","pages":"Page 16"},"PeriodicalIF":3.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143343939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}